Dennis W. Zhu, MD
Research Investigator
About

HealthPartners Medical group title: Clinical Cardiac Electrophysiologist

Education: MD, Sichuan Medical College West China University; residency in internal medicine, Baylor College of Medicine; fellowship in cardiovascular disease, Mayo School of Graduate Medical Education; fellowship in clinical cardiac electrophysiology, Mayo School of Graduate Medical Education.

Affiliation
positions
  • Clinical Research Investigator, Cardiovascular health
  • Publications While At HealthPartners
    selected publications
    Journal Article
  • Clonal hematopoiesis of indeterminate potential (CHIP): a potential contributor to atherlosclerotic cardio/cerebro-vascular diseases?
    2018
  • Bundle branch re-entrant ventricular tachycardia: novel genetic mechanisms in a life-threatening arrhythmia
    2017
  • Feasibility of an elective cardioversion service led by advanced practice providers without direct cardiologist supervision
    2016
  • Normalization of left ventricular ejection fraction and incidence of appropriate antitachycardia therapy in patients with implantable cardioverter defibrillator for primary prevention of sudden death
    Journal of Cardiac Failure. 2016
  • Atrial flutter with 1:1 conduction in undiagnosed Wolff-Parkinson-White syndrome
    Journal of Emergency Medicine. 2014
  • Bundle branch block re-entry ventricular tachycardia storm during the recovery phase of transient complete heart block
    2013
  • Perioperative management of anticoagulation in patients on warfarin therapy undergoing surgery for cardiac implantable electronic devices
    2013
  • Chronic kidney disease is an independent predictor of pocket hematoma after pacemaker and defibrillator implantation
    Journal of Interventional Cardiac Electrophysiology. 2010
  • Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation
    Heart rhythm. 2010
  • Predictors of appropriate therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death
    Heart International. 2010
  • Sudden cardiac arrest in apical hypertrophic cardiomyopathy
    BMJ Case Reports. 2009
  • The potential mechanisms of bradyarrhythmias associated with AngioJet thrombectomy
    Journal of Invasive Cardiology. 2008
  • Chapter
  • Management of pacemaker and defibrillator complications
    Cardiac pacing and defibrillation: principle and practice. 2008
  • Abstract
  • Management of functional Sprint Fidelis implantable cardioverter-defibrillator leads at cardiac resynchronization therapy-defibrillator generator replacement: an alternative approach for prevention of inappropriate shocks caused by lead failure [abstract]
    Journal of the American College of Cardiology. 2016
  • Normalization of left ventricular ejection fraction is associated with the absence of appropriate anti-tachycardia therapy in patients receiving implantable defibrillators for the primary prevention of sudden death [abstract]
    Circulation. 2013
  • Normalization of left ventricular ejection fraction is associated with the absence of appropriate anti-tachycardia therapy in patients receiving implantable defibrillators for the primary prevention of sudden death [abstract]
    2013
  • High incidence of externalized conductors in St. Jude Medical Riata defibrillator leads: results of fluoroscopic surveillance from a single center in U.S. [abstract]
    Heart rhythm. 2012
  • The safety and efficacy of elective direct current cardioversion of atrial fibrillation and atrial flutter performed by advance practice providers [abstract]
    Heart rhythm. 2012
  • Chronic kidney disease is a significant risk factor of pocket hematoma formation after pacemaker and implantable cardioverter-defibrillator placement independent of anticoagulation and antiplatelet agents [abstract]
    Journal of the American College of Cardiology. 2010
  • Metabolic syndrome predicts poor outcome in patients with systolic heart failure who received implantable-cardioverter defibrillator for primary prevention of sudden cardiac death [abstract]
    Heart rhythm. 2010
  • Continuation of warfarin is superior to holding warfarin with or without bridging therapy in patients undergoing pacemaker and defibrillator placement [abstract]
    Circulation. 2009
  • Safety of cardiac resynchronization therapy device implantation in patients with uninterrupted chronic warfarin therapy [abstract]
    Circulation. 2009
  • presentations
    Presentation
  • A comparison of three different peri-operative anticoagulation strategies during cardiac resynchronization therapy implantation [presentation]
  • Advances in cardiac resynchronization therapy [presentation]
  • Bundle branch reentrant ventricular tachycardia [presentation]
  • Bundle branch reentrant ventricular tachycardia [presentation]
  • Chronic kidney disease is a significant predictor of pocket hematoma complications after pacemaker and implantable cardioverter defibrillator placement independent of anticoagulation and antiplatelet agents [presentation]
  • Continuation of warfarin is superior to holding warfarin with or without bridging therapy in patients undergoing pacemaker and defibrillator placement [presentation]
  • Heart rhythm disorders: fast, slow or irregular [presentation]?
  • How to make your heart healthier [presentation]
  • How to protect your heart [presentation]
  • Management of functional Sprint Fidelis implantable cardioverter-defibrillator leads at cardiac resynchronization therapy-defibrillator generator replacement: an alternative approach for prevention of inappropriate shocks caused by lead failure [presentation]
  • Metabolic syndrome predicts poor outcome in patients with systolic heart failure who received implantable-cardioverter defibrillator for primary prevention of sudden cardiac death [presentation]
  • Normalization of left ventricular ejection fraction is associated with the absence of appropriate anti-tachycardia therapy in patients receiving implantable defibrillators for the primary prevention of sudden death [presentation]
  • Perioperative management of anticoagulation in patients on warfarin therapy undergoing EP and CV procedures [presentation]
  • Perioperative management of anticoagulation in patients undergoing cardiac procedures [presentation], HealthPartners Institute for Education and Research 35th Annual Cardiovascular Conference
  • Predictors and prognosis of worsening renal function in patients hospitalized with acute diastolic heart failure and treated with intravenous furosemide [presentation]
  • Safety of cardiac resynchronization therapy device implantation in patients with uninterrupted chronic warfarin therapy [presentation]
  • Safety of coronary angiography and percutaneous coronary intervention in patients on uninterrupted warfarin therapy: a systematic review and meta-analysis [presentation]
  • The safety and efficacy of elective direct current cardioversion of atrial fibrillation and atrial flutter performed by advance practice providers [presentation]
  • Contact
    full name
  • Dennis W. Zhu, MD
  • Quick Info
     
    Collaboration
    More Info